MCRIi001-A-2

MCRIi001-A-SOX9tdTom, PB001-SOX9tdTom

General#

Cell Line

hPSCreg Name
MCRIi001-A-2
Alternative name(s)
MCRIi001-A-SOX9tdTom, PB001-SOX9tdTom
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 7th June 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Murdoch Children's Research Institute (MCRI)
Owner Murdoch Children's Research Institute (MCRI)
Distributors
Derivation country Australia

External Databases

BioSamples SAMEA5873308
Cellosaurus CVCL_WU54
CLO CLO_0102771
Wikidata Q95986993

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Cell line can only be used in: To be agreed via MTA
Research: allowed
Clinical: not allowed
Commercial: not allowed
Subclone of

Donor Information#

General Donor Information

Sex male
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA4966491

Ethics#

Also have a look at the ethics information for the parental line MCRIi001-A .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? Yes
Constraints for use or distribution Only available for agreed collaborative projects and with an MTA in place

hIPSC Derivation#

General

The source cell information can be found in the parental cell line MCRIi001-A.

Reprogramming method

Vector type None

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Surface coating Non coated
Feeder cells MEF
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 95 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: DMEM/F12
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
Glutamax 2 mM
NEAA 1 %
b-mercaptoethanol 0.1 mM
FGF2 50 ng/ml
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation#

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
Molcular karyotype arr(1-22)x2(XY)x1
Passage number: 2
Karyotyping method: Molecular karyotyping by SNP array

Other Genotyping (Cell Line)

Genetic Modification#

Genetic modifications not related to a disease
sox9 (target)
Transgene expression
Td-Tomato fluorescence reporter gene insertion downstream of SOX9 gene
CRISPR-associated (CRISPR/Cas) System